1 / 24

NDA 50-772 TLC D-99 Doxorubicin HCL Liposome The Liposome Company, Inc.

NDA 50-772 TLC D-99 Doxorubicin HCL Liposome The Liposome Company, Inc. Proposed Indication: “First line treatment of metastatic breast cancer in combination with cyclophosphamide”. TLC D-99 Review Team. Administrative History. 11/24/87 IND # 30,894 submitted

adeline
Télécharger la présentation

NDA 50-772 TLC D-99 Doxorubicin HCL Liposome The Liposome Company, Inc.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. NDA 50-772TLC D-99Doxorubicin HCL LiposomeThe Liposome Company, Inc. Proposed Indication: “First line treatment of metastatic breast cancer in combination with cyclophosphamide”

  2. TLC D-99 Review Team

  3. Administrative History 11/24/87 IND # 30,894 submitted 2/4/94 End of Phase II meeting 6/30/98 Guidance meeting (Study 2 closed) 11/3/98 Study 3 included as a supportive trial 12/14/98 NDA submitted

  4. In 1994 the Agency agreed to: • Utilize response rate as the primary basis of efficacy comparison. • Utilize proportional analyses rather than absolute increments (15%). • Evaluate response rates using 95% C.I. of the odds ratio. • Utilize 1-sided C.I. for this response comparison. • Utilize a lower bound of this C.I. (R = 0.75)

  5. Administrative History • June 30,1998 Guidance meeting (Study 2 closed) • Nov 3, 1998 Study 3 included as a supportive trial • Dec 14, 1998 NDA submitted

  6. Study Design and Endpoints

  7. The dose of epirubicin used in study 3 has not been established equivalent to doxorubicin for the following reasons: • Doses of 100 to 120 mg/m2 have been used in combination therapy and were more effective than the lower doses. • Epirubicin may be not equivalent to doxorubicin on a mg per mg basis. • Epirubicin at 75 mg/m2has not been demonstrated to be a standard treatment for first line metastatic breast cancer.

  8. Survival CurveEpirubicin Study

  9. Efficacy ResultsStudies 1 and 2

  10. SurvivalStudies 1 and 2

  11. Study 1Survival

  12. Study 2Survival

  13. Study 2Multivariate analysis • Prognostic factors for covariate adjustment : (J Clin Oncol 16:2401-2408, 1998) • Disease Free Interval • AST level • Liver metastases • Previous adjuvant chemotherapy • Treatment effect with covariates: Risk Ratio:0.70p-value :0.034 • Covariates adjustment for progesterone and estrogen receptors:p-value 0.05

  14. Time to ProgressionStudies 1 and 2

  15. Efficacy ResultsStudy 3

  16. SurvivalStudy 3

  17. Time to ProgressionStudy 3

  18. SummaryStudy 3 • Similar response rates and survival • Trend toward longer TTP for TLC arm • Relatively low dose of Epirubicin • Small study stopped prematurely

  19. Cardiotoxicity

  20. Summary of Toxicities

  21. Regulatory issues • Studies 1 and 2 showed less cardiotoxicity TLC arm • Non-inferiority (Ratio of Response Rates): • Study 1: 0.78 • Study 2: 0.62

  22. Regulatory issues Overall survival: Study 1: HR: 1.01 95% CI: 0.71 Study 2: p= 0.07 HR: 0.75 95% CI: 0.54 The comparator arm on Study 3 is not adequate

  23. Reviewer Conclusions • Insufficient evidence to support TLC D-99 for first line treatment of metastatic breast cancer • Non-inferior R.R in Study 1 • Negative Survival trend Study 2 • Study 3 inadequate comparator • TLC D-99 less cardiotoxic, but this endpoint alone does not support the proposed indication

More Related